Leuprolide

Prostate Cancer

Leuprolide is used for the palliative treatment of advanced prostate cancer. It helps manage the disease by lowering testosterone levels, which can slow the growth of cancer cells and reduce related symptoms.

Endometriosis and Uterine Fibroids

In women, leuprolide is used to treat conditions related to the uterine lining and growths:

• Endometriosis: It is used to reduce pain and the size of endometrial tissue growths.
• Uterine Fibroids: It is used to shrink fibroids and improve anemia (low red blood cell count) caused by heavy bleeding, often in preparation for surgery.

Central Precocious Puberty

Leuprolide is prescribed for children with central precocious puberty (CPP). This condition causes puberty to begin at an unusually early age. The medication helps delay the physical signs of puberty until a more typical age is reached.

Hormone Suppression

Leuprolide belongs to a class of medications known as gonadotropin-releasing hormone (GnRH) agonists. It works by acting on the pituitary gland, which is the part of the brain that controls the production of sex hormones.

When treatment first begins, leuprolide causes a temporary surge in hormone levels. However, with continuous and regular use, the medication causes the pituitary gland to stop responding to hormone-releasing signals. This leads to a significant drop in the production of testosterone in men and estrogen in women.

Effects on Specific Conditions

• Prostate Cancer: Most prostate cancers need testosterone to grow. By lowering testosterone to very low levels, leuprolide helps slow or stop the growth of cancer cells.
• Endometriosis and Uterine Fibroids: These conditions are often fueled by estrogen. Reducing estrogen levels helps shrink fibroid tissue and reduces the growth of the uterine lining outside the uterus.
• Precocious Puberty: In children with early-onset puberty, the medication suppresses the hormones that trigger physical development, delaying the process until a more appropriate age.

Common Side Effects

Many people using leuprolide experience mild to moderate side effects as their body adjusts to the medication. Common symptoms include:

• Hot flashes and increased sweating
• Pain, swelling, bruising, or redness at the injection site
• Headache, dizziness, or general fatigue
• Nausea, constipation, or stomach upset
• Joint, muscle, or bone pain
• Changes in breast size or breast tenderness
• Decreased sexual desire or impotence
• Vaginal dryness, itching, or spotting in women
• Mood swings or depression

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious symptoms:

• Signs of an allergic reaction, such as hives, difficulty breathing, or swelling of the face, lips, or throat
• New or worsening bone pain, or difficulty moving
• Numbness, tingling, or weakness in the legs or feet
• Difficulty urinating, painful urination, or blood in the urine
• Chest pain, pressure, or sudden shortness of breath
• Sudden, severe headache, confusion, or vision changes
• Signs of high blood sugar, such as extreme thirst or frequent urination
• Seizures
• Rapid or irregular heartbeat

When used in children for early puberty, there may be a temporary increase in signs of puberty (such as light vaginal bleeding or breast enlargement) during the first few weeks of treatment before the condition begins to improve.

Tumor Flare

During the initial weeks of treatment, leuprolide causes a temporary surge in hormone levels. This can lead to a tumor flare, where symptoms of the underlying condition temporarily worsen. In patients with prostate cancer, this may cause bone pain, urinary obstruction, or spinal cord compression. Close clinical monitoring is typically required during the start of therapy.

Cardiovascular and Metabolic Effects

Treatment with leuprolide is associated with an increased risk of developing diabetes or experiencing serious cardiovascular events, such as heart attack, stroke, or sudden cardiac death. Healthcare providers may monitor blood glucose levels and cardiovascular health periodically during treatment.

Bone Mineral Density

Long-term use of this medication can lead to a reduction in bone mineral density. This loss may be permanent and increases the risk of developing osteoporosis or experiencing bone fractures.

Psychiatric and Neurological Risks

• Mood Changes: Emotional instability, depression, and irritability have been reported. In pediatric patients, there is a risk of suicidal ideation and behavior.
• Seizures: There have been reports of seizures in patients taking leuprolide, including those without a history of epilepsy or predisposing risk factors.
• Pseudotumor Cerebri: Pediatric patients may develop increased intracranial pressure (idiopathic intracranial hypertension), which can cause headaches, nausea, and vision loss.

Pituitary Apoplexy

Rarely, a condition called pituitary apoplexy may occur, usually within two weeks of the first dose. This is a medical emergency characterized by sudden headache, vomiting, visual changes, and hormonal dysfunction.

Pregnancy and Fetal Risk

Leuprolide can cause fetal harm and is contraindicated for use during pregnancy. Individuals of childbearing potential are typically advised to use effective non-hormonal contraception during treatment and for a period after the final dose.

Pregnancy

Leuprolide is generally contraindicated during pregnancy. Clinical data suggests that exposure to this medication while pregnant may increase the risk of miscarriage or cause harm to the developing fetus. Healthcare providers typically require a pregnancy test before starting treatment to ensure the patient is not pregnant.

While leuprolide usually stops ovulation and menstruation, it is not considered a reliable form of birth control. Patients of childbearing potential are advised to use effective, non-hormonal contraceptive methods, such as condoms or a diaphragm, throughout the course of treatment. If a patient becomes pregnant while receiving leuprolide, they should notify their healthcare provider immediately to discuss the potential risks.

Breastfeeding

It is not currently known whether leuprolide is excreted in human breast milk. Because many drugs are excreted in milk and there is a potential for serious adverse reactions in nursing infants, a decision must be made whether to discontinue breastfeeding or to discontinue the drug. Patients should consult with a healthcare professional to weigh the benefits of the medication against the potential risks to the infant.

Injectable Formulations

Leuprolide is administered by injection or through a surgical implant. The frequency of administration depends on the specific formulation prescribed by a healthcare provider.

Subcutaneous Injections

• Daily Injection: A solution for daily administration under the skin.
• Extended-Release Gel: A formulation injected under the skin that releases medication over 1, 3, 4, or 6 months.
• Subcutaneous Implant: A small reservoir placed under the skin of the upper arm that provides continuous medication for 12 months.

Intramuscular Injections

• Depot Suspension: Long-acting injections administered into the muscle. These formulations are available in strengths designed to last for 1, 3, or 4 months.

FDA Approval and Indications

Leuprolide was first approved by the U.S. Food and Drug Administration (FDA) in 1985. It is currently approved for several specific medical uses:

• Palliative treatment of advanced prostate cancer.
• Management of endometriosis, including pain relief and reduction of endometrial lesions.
• Treatment of children with central precocious puberty (CPP).
• Preoperative treatment of patients with anemia caused by uterine fibroids, typically used in combination with iron therapy.

Safety Communications and Warnings

In 2017, the FDA identified a potential signal of serious risk regarding convulsions associated with leuprolide acetate through the FDA Adverse Event Reporting System (FAERS). The agency continues to monitor these reports to evaluate the need for further regulatory action.

Leuprolide is contraindicated during pregnancy because it may cause fetal harm. It is often classified as Pregnancy Category X for certain indications. While it does not currently require a Risk Evaluation and Mitigation Strategy (REMS) program, clinical monitoring is required for the "tumor flare" phenomenon, where a temporary increase in testosterone or estrogen levels occurs at the start of treatment, potentially worsening symptoms briefly.

Factors Influencing Cost

Several factors determine the total cost of leuprolide treatment, including:

• Formulation and Brand: Prices differ between brand-name products and generic versions. Different formulations, such as those for daily use versus long-acting injections that last several months, also have different price points.
• Dosage Frequency: Long-acting kits (administered every 3, 4, or 6 months) may have a higher upfront cost than monthly injections, though they require fewer administrations.
• Administration Fees: Because many forms of leuprolide must be administered by a healthcare professional, the total cost often includes office visit fees and clinical administration charges.

Insurance and Medicare

Most insurance plans, including Medicare and Medicaid, cover leuprolide when it is prescribed for a medically necessary condition. Depending on the specific plan and how the drug is administered, it may be covered under medical benefits (often the case for injections given in a doctor's office) or prescription drug benefits. Patients should verify their out-of-pocket costs, such as deductibles or coinsurance, with their insurance provider.

Financial Assistance Programs

Many manufacturers offer patient assistance programs or co-pay savings cards to help eligible patients manage the cost of leuprolide. These programs are often designed for individuals who are uninsured or have high out-of-pocket expenses. Eligibility is typically based on income and insurance status.